Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 36Neoplasms, Plasma Cell 8Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Recurrence 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Intraocular Lymphoma 2Immunoglobulin Light-chain Amyloidosis 2Immunoblastic Lymphadenopathy 2Burkitt Lymphoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Renal Insufficiency, Chronic 1Renal Insufficiency 1Proteostasis Deficiencies 1

Interventions

Lenalidomide 5Dexamethasone 4fludarabine phosphate 2daratumumab 2Whole-Body Irradiation 2Cyclophosphamide 2Calcium Dobesilate 2talquetamab 1selinexor 1ixazomib 1isatuximab 1fludarabine 1Transplantation, Autologous 1Sirolimus 1Rituximab 1Mycophenolic Acid 1Melphalan 1Bortezomib 1Blood Specimen Collection 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Bendamustine Hydrochloride × Plasma cell × Clear all
NCT03524235 2024-11-12

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Cedars-Sinai Medical Center

Phase 1 Completed
20 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡